Egis Pharmaceuticals PLC Announces Registration of the First Blood-based CE IVD Precision Medicine Tool for Therapy Selection in Rheumatoid Arthritis
Share Article
Egis Pharmaceuticals PLC (Egis) received the CE In Vitro Diagnostic (IVD) Medical Device Certificate of its PREDYSTIC® Infliximab RA Kit on December 21st, 2020. BUDAPEST, Hungary (PRWEB) March 16, 2021 The PREDYSTIC® Infliximab RA Kit is a first-in-class, CE IVD labelled, molecular biomarker diagnostic system, suitable for predicting infliximab responsiveness in rheumatoid arthritis patients, before the first biological treatment initiation. This novel tool supports the decision making of stakeholders including rheumatologists, patients, payors, and drug developers.
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder affecting around 1% of the worldwide population. Clinical therapeutic options are still limited in their efficacy.
A lady looks at hand sanitiser on a shelf at a pharmacy in Lagos, on March 20, 2020. - The Nigerian government has closed all federal schools in the country, including universities, colleges, and secondary schools as a precautionary measure against the spread of the COVID-19 coronavirus. (Photo by PIUS UTOMI EKPEI / AFP) (Photo by PIUS UTOMI EKPEI/AFP via Getty Images)
By Ikenna Osuoha
Abuja, Dec 28, 2020 National Agency for Food, Drug Administration and Control (NAFDAC) has shut down six pharmaceutical manufacturers for non-compliance with Good manufacturing Practice (GMP).
Prof. Mojisola Adeyeye, director general of the Agency, said this in a statement by Mr Sayo Akintola, Resident Media Consultant, NAFDAC, and made available to the News Agency of Nigeria (NAN) on Monday, in Abuja.
NAFDAC shuts down 6 pharmaceutical firms for violating regulations nationalaccordnewspaper.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nationalaccordnewspaper.com Daily Mail and Mail on Sunday newspapers.
Prof. Mojisola Adeyeye, director general of the agency, said this in a statement by Mr Sayo Akintola, Resident Media Consultant, NAFDAC, and made available to the News Agency of Nigeria (NAN) on Monday, in Abuja.
Adeyeye said that the action of NAFDAC was in accordance with its zero tolerance for circulation of substandard and falsified medicines in the country. The Pharmaceutical companies were shut down following a nationwide surveillance their manufacturing activities. These local manufacturers, in spite of appropriate notification failed to meet minimum Good Manufacturing Practice (GMP) standards in line with extant requirements to assure the quality, safety and efficacy of pharmaceutical products, she said.